ArticleRespirology case reports2025
Pembrolizumab-Induced Severe Pneumonitis in a Patient With Lung Adenocarcinoma After Umbilical Cord Blood Transplantation: A Case Report.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pembrolizumab-Induced Severe Pneumonitis in a Patient With Lung Adenocarcinoma After Umbilical Cord Blood Transplantation: A Case Report.Respirology case reports · 2025Article
- COVID-19 Vaccine-Induced Severe Pneumonitis.Respirology case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) are essential treatments for lung cancer, but their safety following allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains unclear. We report a case of a 66-year-old man who underwent umbilical cord blood transplantation for acute lymphoblastic leukaemia and later developed lung adenocarcinoma. Pembrolizumab monotherapy was initiated, but the patient developed severe steroid-refractory immune-related pneumonitis, leading to mortality 56 days after treatment initiation. Given the scarcity of reports on ICI use in lung cancer patients with prior HSCT, this case highlights critical safety considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.